NEW YORK--(BUSINESS WIRE)--The Klein Law Firm announces the commencement of an investigation of Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) concerning possible violations of federal securities laws.
On November 6, 2015, Dr. Reddy’s announced that it had received a warning letter issued by the U.S. Food and Drug Administration concerning inadequate quality control standards at three of Dr. Reddy’s manufacturing plants in India. Then on August 10, 2017, Dr. Reddy’s disclosed that the Regierung von Oberbayern (the district government of Upper Bavaria) did not renew the good manufacturing practices compliance certificate of a manufacturing unit of Dr. Reddy’s German subsidiary Betapharm Arzneimittel, located in India. Following this news, shares of Dr. Reddy’s stock was down more than 5% on intraday trading on August 10, 2017.
If you suffered a loss in Dr. Reddy’s and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/RDY-Info-Request-Form-203.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
